ライフサイエンスコーパス: gammopathy

1 ry amyloidosis with a concomitant monoclonal gammopathy.

2 marrow and the presence of an IgM monoclonal gammopathy.

3 racutaneous manifestations, and a monoclonal gammopathy.

4 me (FS) is a rare complication of monoclonal gammopathy.

5 era of individuals with a form of monoclonal gammopathy.

6 ge, 42-80 years) of the IBM patients without gammopathy.

7 ogy in patients who do not have a monoclonal gammopathy.

8 of patients will have persistent monoclonal gammopathy.

9 amate than patients with indolent monoclonal gammopathies.

10 ) cells across the progression of monoclonal gammopathies.

11 implicated in the pathogenesis of monoclonal gammopathies.

12 ed gammopathies and some sporadic monoclonal gammopathies.

13 disease have an increased risk of monoclonal gammopathies.

14 replication in the persistence of monoclonal gammopathy.1 It has been known for some time that patien

15 nts (91.9%) with monoclonal immunoglobulin G gammopathy, 20 (58.8%) had kappa light chains.

16 Further investigation revealed a monoclonal gammopathy, a unique patterning of subcutaneous fat reti

17 rized by urticarial exanthema and monoclonal gammopathy accompanied by systemic symptoms such as feve

18 ) are preceded by an asymptomatic monoclonal gammopathy (AMG), classified as either monoclonal gammop

19 y underlie both Gaucher's disease-associated gammopathies and some sporadic monoclonal gammopathies.

20 symptomatic patients) had both a monoclonal gammopathy and a hereditary variant.

21 alignancy characterized by an IgM monoclonal gammopathy and bone marrow (BM) infiltration with lympho

22 (21%) patients were positive for monoclonal gammopathy and had a faster rate of recurrence and graft

23 ew the causal association between monoclonal gammopathy and neuropathy, and critically review the rec

24 unknown, but in many patients the monoclonal gammopathy and other B-cell abnormalities can be reverse

25 on have an increased incidence of monoclonal gammopathy and plasma cell dyscrasias.2,3 The exact mech

26 a causal relationship between the monoclonal gammopathy and the renal damage and because the signific

27 ambda J lambda rearrangements in lambda-type gammopathies, and that of other Abs to thymus-dependent

28 cterized by an urticarial rash, a monoclonal gammopathy, and clinical, histological, and biological s

29 current urticarial rash and a monoclonal IgM gammopathy, and two of the following minor criteria: rec

30 ey diseases associated with other monoclonal gammopathies are being recognized.

31 Monoclonal gammopathies are frequently complicated by kidney lesion

32 The IgG and IgA monoclonal gammopathies are rarely associated with specific neuropa

33 IgD monoclonal gammopathies are uncommon.

34 (MGUS) is the most commonly found monoclonal gammopathy associated with neuropathy.

35 by recurrent urticarial rash and monoclonal gammopathy, associated with clinical and biological sign

36 stics of human disease, including monoclonal gammopathy, BM infiltration with lytic bone lesions, and

37 In patients with monoclonal gammopathies, C-reactive protein may be a more specific

38 2% of age-matched controls, had a monoclonal gammopathy characterized as IgG lambda in 9 patients, Ig

39 (MIDD) is a rare complication of monoclonal gammopathy characterized by deposition of monoclonal Ig

40 ain human sera from patients with monoclonal gammopathies contain factors that induce myelin repair i

41 In patients with monoclonal IgG gammopathies, diagnosis is definite if three minor crite

42 In conclusion, FS associated with monoclonal gammopathy does not appear to confer an additional risk

43 in 305 patients with asymptomatic monoclonal gammopathy enrolled in S0120 under the auspices of SWOG.

44 ical and laboratory findings with monoclonal gammopathy evaluation and, if indicated, TTR gene testin

45 pheral neuropathy associated with monoclonal gammopathies has been advanced by recent clinical studie

46 t not nonprogressive myeloma or premalignant gammopathy, have a marked deficiency of ligand-dependent

47 iated skeletal destruction, serum monoclonal gammopathy, immune suppression, and end-organ sequelae.

48 tor in child GP patients and with monoclonal gammopathy in adult GP patients, who frequently showed I

49 The high frequency of monoclonal gammopathy in adult patients with C3 glomerulopathy (C3G

50 ion ameliorates Gaucher's disease-associated gammopathy in mice.

51 rasias.2,3 The exact mechanism of monoclonal gammopathy in patients with HIV infection is unknown, bu

52 Monoclonal gammopathy in several patients may have potential clinic

53 lification was detected in 67% of monoclonal gammopathies, including monoclonal gammopathy of undeter

54 globulin in 33% of sporadic human monoclonal gammopathies is also specific for the lysolipids LGL1 an

55 ical progression in patients with monoclonal gammopathies is associated with an acquired but potentia

56 l disease, the persistence of the monoclonal gammopathy is associated with high rates of recurrence a

57 d because the significance of the monoclonal gammopathy is no longer undetermined.

58 mouse models of Gaucher's disease-associated gammopathy is reactive against lyso-glucosylceramide (LG

59 ears before diagnosis to detect a monoclonal gammopathy (M-Ig).

60 A high prevalence of monoclonal gammopathy (MG) has been observed in HIV-infected patien

61 ls compared with the marrow in preneoplastic gammopathy (monoclonal gammopathy of undetermined signif

62 ere we show that patients with preneoplastic gammopathy mount a vigorous T cell response to autologou

63 tudies might seek to identify, with biclonal gammopathy multiple myeloma as an investigative model, t

64 study, we identified patients with biclonal gammopathy multiple myeloma by central laboratory analys

65 Biclonal gammopathy multiple myeloma is characterised by the coex

66 44 patients with biclonal gammopathy multiple myeloma with IgG or IgA MGUS clones

67 results show that, in patients with biclonal gammopathy multiple myeloma, anti-multiple myeloma thera

68 py in patients newly diagnosed with biclonal gammopathy multiple myeloma.

69 d tumor bed in 23 patients with premalignant gammopathy, nonprogressive myeloma, or progressive multi

70 only 15% of patients, included 21 monoclonal gammopathies of renal significance; 15 multiple myelomas

71 paraprotein target (paratargs) in monoclonal gammopathies of undetermined significance (MGUS), multip

72 n can be identified as in myeloma/monoclonal gammopathies of undetermined significance (MGUS).

73 tients (29 AL, 23 MM, and 9 MGUS [monoclonal gammopathies of undetermined significance]) were studied

74 Recently, the term monoclonal gammopathy of renal significance (MGRS) was introduced t

75 Hematological diagnosis was monoclonal gammopathy of renal significance in 30 (60%), multiple m

76 We think the term monoclonal gammopathy of renal significance is most helpful to indi

77 as determined in 63 patients with monoclonal gammopathy of uncertain significance (MGUS) and 198 pati

78 s of normal plasma cells (PCs) to monoclonal gammopathy of uncertain significance (MGUS) and multiple

79 Aberrant demethylation in monoclonal gammopathy of uncertain significance occurred primarily

80 bjects representing premalignant (monoclonal gammopathy of uncertain significance), early, and advanc

81 CGH on 25 cases of MM, 4 cases of monoclonal gammopathy of uncertain significance, and 1 case of Wald

82 ent course of disease that mimics monoclonal gammopathy of undermined significance, whereas others ha

83 oma (SMM) bridges the gap between monoclonal gammopathy of undetermined significance (a mostly premal

84 with WM and 10 patients with IgM monoclonal gammopathy of undetermined significance (IgM MGUS).

85 58 patients with WM, 77 with IgM monoclonal gammopathy of undetermined significance (IgM-MGUS), 84 w

86 s from subjects with MM (n = 16), monoclonal gammopathy of undetermined significance (MGUS) (n = 6),

87 somes from multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS) and healt

88 4+ CD25+ T cells in patients with monoclonal gammopathy of undetermined significance (MGUS) and in pa

89 arly pathogenesis of premalignant monoclonal gammopathy of undetermined significance (MGUS) and malig

90 Monoclonal gammopathy of undetermined significance (MGUS) and multi

91 rrow specimens from patients with monoclonal gammopathy of undetermined significance (MGUS) and multi

92 ignant non-immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (MGUS) and multi

93 ly expressed in plasma cells from monoclonal gammopathy of undetermined significance (MGUS) and multi

94 eceded by the precursor states of monoclonal gammopathy of undetermined significance (MGUS) and smold

95 ant plasma cell dyscrasia such as monoclonal gammopathy of undetermined significance (MGUS) and smold

96 Patients with monoclonal gammopathy of undetermined significance (MGUS) are at in

97 Monoclonal gammopathy of undetermined significance (MGUS) can progr

98 ering of the precursor condition, monoclonal gammopathy of undetermined significance (MGUS) has been

99 lls in the blood of patients with monoclonal gammopathy of undetermined significance (MGUS) has been

100 r et al showed that patients with monoclonal gammopathy of undetermined significance (MGUS) have incr

101 e reported a higher prevalence of monoclonal gammopathy of undetermined significance (MGUS) in Africa

102 Monoclonal gammopathy of undetermined significance (MGUS) is a comm

103 Monoclonal gammopathy of undetermined significance (MGUS) is a prem

104 Monoclonal gammopathy of undetermined significance (MGUS) is an asy

105 Monoclonal gammopathy of undetermined significance (MGUS) is an asy

106 Monoclonal gammopathy of undetermined significance (MGUS) is associ

107 Monoclonal gammopathy of undetermined significance (MGUS) is define

108 We examined whether monoclonal gammopathy of undetermined significance (MGUS) is increa

109 Monoclonal gammopathy of undetermined significance (MGUS) is presen

110 IgM monoclonal gammopathy of undetermined significance (MGUS) is the mo

111 Whether this dichotomy exists in monoclonal gammopathy of undetermined significance (MGUS) is uncert

112 The association of obesity with monoclonal gammopathy of undetermined significance (MGUS) is unknow

113 Monoclonal gammopathy of undetermined significance (MGUS) is, in ma

114 A monoclonal gammopathy of undetermined significance (MGUS) occurs in

115 to quantitate adverse outcomes of monoclonal gammopathy of undetermined significance (MGUS) of the im

116 pathy (AMG), classified as either monoclonal gammopathy of undetermined significance (MGUS) or asympt

117 Unlike monoclonal gammopathy of undetermined significance (MGUS) or non-Ho

118 At diagnosis, most patients had monoclonal gammopathy of undetermined significance (MGUS) or smolde

119 eceded by precursor states termed monoclonal gammopathy of undetermined significance (MGUS) or smolde

120 (MM) patients (n = 8740) and 5652 monoclonal gammopathy of undetermined significance (MGUS) patients

121 in 90% of immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (MGUS) patients.

122 Monoclonal gammopathy of undetermined significance (MGUS) progresse

123 ith AL-amyloidosis secondary to a monoclonal gammopathy of undetermined significance (MGUS) referred

124 ation from immunoglobulin-M (IgM) monoclonal gammopathy of undetermined significance (MGUS) remain un

125 Monoclonal gammopathy of undetermined significance (MGUS) represent

126 patients is more consistent with monoclonal gammopathy of undetermined significance (MGUS) than with

127 study the risk of progression of monoclonal gammopathy of undetermined significance (MGUS) to lympho

128 y a role in the transformation of monoclonal gammopathy of undetermined significance (MGUS) to MM.

129 The transformation from monoclonal gammopathy of undetermined significance (MGUS) to multip

130 s that determine progression from monoclonal gammopathy of undetermined significance (MGUS) to multip

131 hat the clinical progression from monoclonal gammopathy of undetermined significance (MGUS) to multip

132 leading the transformation of the monoclonal gammopathy of undetermined significance (MGUS) to myelom

133 ple myeloma (MM) and premalignant monoclonal gammopathy of undetermined significance (MGUS) tumors: a

134 untreated active myeloma, 14 had monoclonal gammopathy of undetermined significance (MGUS), 10 had d

135 om two out of eight patients with monoclonal gammopathy of undetermined significance (MGUS), a precur

136 Monoclonal gammopathy of undetermined significance (MGUS), a precur

137 The prevalence of monoclonal gammopathy of undetermined significance (MGUS), a premal

138 detected in 5 of 5 patients with monoclonal gammopathy of undetermined significance (MGUS), an early

139 sed multiple myeloma (MM), 5 with monoclonal gammopathy of undetermined significance (MGUS), and 31 h

140 multiple myeloma, three cases of monoclonal gammopathy of undetermined significance (MGUS), and five

141 da immunoglobulin light chains in monoclonal gammopathy of undetermined significance (MGUS), as detec

142 ones of a subset of patients with monoclonal gammopathy of undetermined significance (MGUS), asymptom

143 ties to multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS), but its

144 tions have been identified in the monoclonal gammopathy of undetermined significance (MGUS), but thei

145 In 728 Swedish cases of monoclonal gammopathy of undetermined significance (MGUS), followed

146 l clone, referred to as secondary monoclonal gammopathy of undetermined significance (MGUS), have bee

147 Plasma cell dyscrasias, including monoclonal gammopathy of undetermined significance (MGUS), multiple

148 n plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS), smolderi

149 eloma is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS), which is

150 myeloma to a benign form known as monoclonal gammopathy of undetermined significance (MGUS), which re

151 e an increased fracture risk with monoclonal gammopathy of undetermined significance (MGUS).

152 from a premalignant stage called monoclonal gammopathy of undetermined significance (MGUS).

153 applicators to assess the risk of monoclonal gammopathy of undetermined significance (MGUS).

154 logy of multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS).

155 onoclonal gammopathies, including monoclonal gammopathy of undetermined significance (MGUS).

156 m a common benign PC tumor called Monoclonal Gammopathy of Undetermined Significance (MGUS).

157 a premalignant condition known as monoclonal gammopathy of undetermined significance (MGUS).

158 preceded by the precursor state, monoclonal gammopathy of undetermined significance (MGUS).

159 myeloma and its precursor state, monoclonal gammopathy of undetermined significance (MGUS); however,

160 than 500 untreated patients with monoclonal gammopathy of undetermined significance (MGUS; n = 14),

161 s relatively common and occurs in monoclonal gammopathy of undetermined significance (MGUS; n=17), sm

162 l [CI], 1.31-17.86; P = .018) and monoclonal gammopathy of undetermined significance (OR, 5.94; 95% C

163 rrow in preneoplastic gammopathy (monoclonal gammopathy of undetermined significance [MGUS]).

164 ls (B cells, normal plasma cells, monoclonal gammopathy of undetermined significance [MGUS], presenta

165 They are seen rarely as a monoclonal gammopathy of undetermined significance and are present

166 ypic profiles between AL and both monoclonal gammopathy of undetermined significance and MM PCs.

167 te potential (CHIP), analogous to monoclonal gammopathy of undetermined significance and monoclonal B

168 one marrow involvement similar to monoclonal gammopathy of undetermined significance at diagnosis, th

169 SMM is distinguished from monoclonal gammopathy of undetermined significance by a much higher

170 healthy donors and patients with monoclonal gammopathy of undetermined significance or other plasma

171 ment cells in transformation from monoclonal gammopathy of undetermined significance or smoldering mu

172 rum adiponectin concentrations in monoclonal gammopathy of undetermined significance patients who sub

173 n that parallels progression from monoclonal gammopathy of undetermined significance to MM.

174 An IgG kappa monoclonal gammopathy of undetermined significance was found.

175 Plasma cells in 10 patients with monoclonal gammopathy of undetermined significance were not stained

176 s can help identify patients with monoclonal gammopathy of undetermined significance who are developi

177 characteristics that evolves from monoclonal gammopathy of undetermined significance, a highly preval

178 S from neuropathy associated with monoclonal gammopathy of undetermined significance, additional crit

179 in amyloidosis, multiple myeloma, monoclonal gammopathy of undetermined significance, and non-parapro

180 n from the non-malignant disorder monoclonal gammopathy of undetermined significance, are poorly unde

181 amyloidosis, multiple myeloma and monoclonal gammopathy of undetermined significance, immunoreactive

182 reexisting plasma cell disorders, monoclonal gammopathy of undetermined significance, or smoldering m

183 plasma cells from healthy donors, monoclonal gammopathy of undetermined significance, smoldering MM,

184 f paraproteinemia in a setting of monoclonal gammopathy of undetermined significance, smoldering plas

185 tients with IgG/IgA (but not IgM) monoclonal gammopathy of undetermined significance, supporting a ro

186 ive premalignant condition termed monoclonal gammopathy of undetermined significance.

187 eloma cells, even in asymptomatic monoclonal gammopathy of undetermined significance.

188 ave shown limited efficacy in IgM monoclonal gammopathy of undetermined significance.

189 myeloproliferative disorder, and monoclonal gammopathy of undetermined significance.

190 Monoclonal gammopathy of unknown significance (MGUS) and smoldering

191 tion of SOCS1 and SYK; (5) MM and monoclonal gammopathy of unknown significance (MGUS) had infrequent

192 ients with MM, chronic leukemias, monoclonal gammopathy of unknown significance (MGUS), PBC, and heal

193 Although the high prevalence of a monoclonal gammopathy of unknown significance in SCLS suggests a pa

194 the limited plasma cell disorder monoclonal gammopathy of unknown significance or in nonmyeloma hema

195 patients with multiple myeloma or monoclonal gammopathy of unknown significance sequentially underwen

196 5 with smoldering MM, and 4 with monoclonal gammopathy of unknown significance) and 20 individuals w

197 T-cell populations, analogous to monoclonal gammopathy of unknown significance.

198 s with indolent smoldering MM and monoclonal gammopathy of unknown significance.

199 a, marginal-zone lymphoma, or IgM monoclonal gammopathy of unknown significance.

200 s through a premalignant state of monoclonal gammopathy of unknown significance; however, the molecul

201 onstellation of lambda-restricted monoclonal gammopathy, plasma cell rimming around lymphoid aggregat

202 Polyclonal gammopathy pretransplant is common with 17% of all patie

203 Paraproteinemia relates to monoclonal gammopathy-producing pathologic antibodies with serous m

204 xenografts from patients with preneoplastic gammopathy showed progressive growth, suggesting that th

205 tiple myeloma (MM) are 2 distinct monoclonal gammopathies that involve the same cellular compartment:

206 RS) was introduced to distinguish monoclonal gammopathies that result in the development of kidney di

207 s, a form of renal involvement by monoclonal gammopathy that mimics immune-complex glomerulonephritis

208 iple myeloma is the most frequent monoclonal gammopathy to involve the kidney; however, a growing num

209 ge renal disease and known benign monoclonal gammopathy underwent kidney transplantation at Westchest

210 nt somatic mutation in benign monoclonal IgM gammopathy, Waldenstrom's macroglobulinemia, and diffuse

211 The mean age of IBM patients with gammopathy was 60.6 years (range, 35-77 years), compared

212 Monoclonal gammopathy was of IgG type in 47 (94%) patients.

213 ge, is frequently associated with monoclonal gammopathies, which often recognize various muscle compo